Story perspectives

FDA Accelerates Approval of Vera’s First Dual-Inhibitor Trutakna for IgAN

7/10/2026

Summary

Story summary

FDA granted accelerated approval to Vera Therapeutics' Trutakna (atacicept) for IgA nephropathy at risk of progression.
Trutakna, priced at $425,000 a year (above Otsuka's $390,000 Voyxact), cut proteinuria 46% from baseline and 42% versus placebo in the ORIGIN 3 trial at 36 weeks.
Trutakna is the first dual BAFF and APRIL inhibitor approved for IgAN.
Otsuka's Voyxact remains the main competitor, with Vera expecting confirmatory Phase 3 eGFR data later this quarter.

1 of 1

Story summary

FDA granted accelerated approval to Vera Therapeutics' Trutakna (atacicept) for IgA nephropathy at risk of progression.
Trutakna, priced at $425,000 a year (above Otsuka's $390,000 Voyxact), cut proteinuria 46% from baseline and 42% versus placebo in the ORIGIN 3 trial at 36 weeks.
Trutakna is the first dual BAFF and APRIL inhibitor approved for IgAN.
Otsuka's Voyxact remains the main competitor, with Vera expecting confirmatory Phase 3 eGFR data later this quarter.